https://t.co/molxSJm5ue "Finally, we and others have shown that Slc25a1 plays an important role in the metabolic rewiring of tumor cells, in chemotherapy resistance and as a mediator of inflammatory signals."
https://t.co/molxSJm5ue "Moreover, mutations of a member of the citrate transporter family in fruit fly, INDY, promote longevity, suggesting that the citrate transport pathway controls life-span."
https://t.co/molxSJm5ue "Various Slc25a1 mutations, spanning throughout the coding region, have also been reported in combined D2-/L2-hydroxyglutaric aciduria, characterized by the pathological accumulation of these aberrant metabolites."
https://t.co/molxSJm5ue "The human Slc25a1 gene maps to chromosome 22.q11.2 and microdeletions of this region give raise to a group of survivable disorders known as Velo-cardio-facial and DiGeorge syndromes."
https://t.co/molxSJm5ue "The mitochondrial citrate carrier, Slc25a1, (or CIC) belongs to a family of ion transporters whose activity has been linked to several pathologic conditions including cancer, aging, and developmental disorders."
Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH #MECFS #LongCovid https://t.co/molxSJm5ue
Novel drug inhibits liver damage, obesity and glucose intolerance in mice fed with high-fat diet https://t.co/K61iPRVG9X Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation ... https://t.co/
RT @melino_G: Inhibition of Slc25a1, reverts #steatosis #glucose intolerance and #inflammation in models of non-alcoholic fatty liver disea…
significance of citrate ( see also paradox on steatosis and FASN inhibition lol), #covid19 #aging https://t.co/DcM7px0K6o
The authors of "Inhibition of the mitochondrial citrate carrier, S…" (https://t.co/gbgUsK8aOg) included RRIDs in their paper! Thank you for making your #methodsmatter. #reproducibility
RT @melino_G: From: Cell Death Differentiation Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intole…
From: Cell Death Differentiation Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH https://t.co/3u9hkOQvXF https://t.co/bKli4C8C7A
RT @melino_G: From: Cell Death Differentiation Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intole…
From: Cell Death Differentiation Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH https://t.co/3u9hkOQvXF https://t.co/7OPUNtXmuu
RT @melino_G: From: Cell Death Differentiation Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intole…
From: Cell Death Differentiation Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH https://t.co/3u9hkOQvXF https://t.co/BLo4ADLWvT
From: Cell Death Differentiation Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH https://t.co/3u9hkOyV67 https://t.co/RgtWnY7Owd
RT @Brunorm84: Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in precli…
RT @melino_G: Inhibition of Slc25a1, reverts #steatosis #glucose intolerance and #inflammation in models of non-alcoholic fatty liver disea…
RT @melino_G: Inhibition of Slc25a1, reverts #steatosis #glucose intolerance and #inflammation in models of non-alcoholic fatty liver disea…
Inhibition of Slc25a1, reverts #steatosis #glucose intolerance and #inflammation in models of non-alcoholic fatty liver disease: a therapeutic target in NAFLD/NASH? Find it out reading this paper on #CellDeath&Differentiation! https://t.co/IcVCaHyCwz
RT @melino_G: Inhibition of Slc25a1, reverts #steatosis #glucose intolerance and #inflammation in models of non-alcoholic fatty liver disea…
Inhibition of Slc25a1, reverts #steatosis #glucose intolerance and #inflammation in models of non-alcoholic fatty liver disease: a therapeutic target in NAFLD/NASH? Find it out reading this paper on #CellDeath&Differentiation! https://t.co/IcVCaHQdV9
RT @melino_G: Inhibition of Slc25a1, reverts #steatosis #glucose intolerance and #inflammation in models of non-alcoholic fatty liver disea…
RT @melino_G: Inhibition of Slc25a1, reverts #steatosis #glucose intolerance and #inflammation in models of non-alcoholic fatty liver disea…
Inhibition of Slc25a1, reverts #steatosis #glucose intolerance and #inflammation in models of non-alcoholic fatty liver disease: a therapeutic target in NAFLD/NASH? Find it out reading this paper on #CellDeath&Differentiation! https://t.co/IcVCaHyCwz
@Eva3034385615
Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH @cddpress https://t.co/aO8a5Ca8jy
RT @melino_G: Inhibition of Slc25a1, reverts #steatosis #glucose intolerance and #inflammation in models of non-alcoholic fatty liver disea…
Inhibition of Slc25a1, reverts #steatosis #glucose intolerance and #inflammation in models of non-alcoholic fatty liver disease: a therapeutic target in NAFLD/NASH? Find it out reading this paper on #CellDeath&Differentiation! https://t.co/IcVCaHQdV9
Inhibition of Slc25a1, reverts #steatosis #glucose intolerance and #inflammation in models of non-alcoholic fatty liver disease: a therapeutic target in NAFLD/NASH? Find it out reading this paper on #CellDeath&Differentiation! https://t.co/IcVCaHyCwz
From: Cell Death Differentiation Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH https://t.co/3u9hkOyV67 https://t.co/ErnrpHLQk3
Inhibition of Slc25a1, reverts #steatosis #glucose intolerance and #inflammation in models of non-alcoholic fatty liver disease: a therapeutic target in NAFLD/NASH? Find it out reading this paper on #CellDeath&Differentiation! https://t.co/IcVCaHQdV9
From: Cell Death Differentiation Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH https://t.co/3u9hkOyV67 https://t.co/kMMfnTSa3v
Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH https://t.co/hoyJR52JYO https://t.co/da8nA3ICH7
RT @melino_G: From: Cell Death Differentiation Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intole…
RT @melino_G: From: Cell Death Differentiation Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intole…
RT @melino_G: From: Cell Death Differentiation Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intole…
From: Cell Death Differentiation Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH https://t.co/3u9hkOyV67 https://t.co/i9jclfYaWe
Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. https://t.co/Zi3dNWANUu
RT @ZaniaStamataki: Exciting new research on the role of the mitochondrial citrate carrier, Slc25a1, in steatosis, glucose intolerance, and…
RT @ZaniaStamataki: Exciting new research on the role of the mitochondrial citrate carrier, Slc25a1, in steatosis, glucose intolerance, and…
Exciting new research on the role of the mitochondrial citrate carrier, Slc25a1, in steatosis, glucose intolerance, and inflammation in NAFLD/NASH https://t.co/0kfUkQQSgX
RT @Brunorm84: Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in precli…
RT @Brunorm84: Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in precli…
RT @Rameca: Our recent publication is finally out https://t.co/I2wGbR4ic0
RT @Brunorm84: Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in precli…
Citrate! https://t.co/tWPj4kZ8NC
RT @Brunorm84: Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in precli…
RT @DanielJDrucker: Mitochondrial citrate flux and experimental liver disease #NAFLD #NASH @cddpress https://t.co/Vfeu2FaFb5
RT @mynameiscormac: Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis and inflammation in preclinical models of N…
RT @gtimblin: Anti-obesity and anti-inflammatory effects of an slc25a1 inhibitor, cool! https://t.co/bZGew3z5Y0
Anti-obesity and anti-inflammatory effects of an slc25a1 inhibitor, cool! https://t.co/bZGew3z5Y0
Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis and inflammation in preclinical models of NAFLD https://t.co/o11lacyvCd
Another important piece of evidence for a signalling function of citrate.
RT @DanielJDrucker: Mitochondrial citrate flux and experimental liver disease #NAFLD #NASH @cddpress https://t.co/Vfeu2FaFb5
RT @DanielJDrucker: Mitochondrial citrate flux and experimental liver disease #NAFLD #NASH @cddpress https://t.co/Vfeu2FaFb5
Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of #NAFLD/#NASH @cddpress https://t.co/aO8a5Ca8jy
RT @DanielJDrucker: Mitochondrial citrate flux and experimental liver disease #NAFLD #NASH @cddpress https://t.co/Vfeu2FaFb5
RT @DanielJDrucker: Mitochondrial citrate flux and experimental liver disease #NAFLD #NASH @cddpress https://t.co/Vfeu2FaFb5
RT @DanielJDrucker: Mitochondrial citrate flux and experimental liver disease #NAFLD #NASH @cddpress https://t.co/Vfeu2FaFb5
RT @Rameca: Our recent publication is finally out https://t.co/I2wGbR4ic0
RT @DanielJDrucker: Mitochondrial citrate flux and experimental liver disease #NAFLD #NASH @cddpress https://t.co/Vfeu2FaFb5
RT @DanielJDrucker: Mitochondrial citrate flux and experimental liver disease #NAFLD #NASH @cddpress https://t.co/Vfeu2FaFb5
RT @DanielJDrucker: Mitochondrial citrate flux and experimental liver disease #NAFLD #NASH @cddpress https://t.co/Vfeu2FaFb5
RT @Rameca: Our recent publication is finally out https://t.co/I2wGbR4ic0
RT @DanielJDrucker: Mitochondrial citrate flux and experimental liver disease #NAFLD #NASH @cddpress https://t.co/Vfeu2FaFb5
Our recent publication is finally out https://t.co/I2wGbR4ic0
RT @DanielJDrucker: Mitochondrial citrate flux and experimental liver disease #NAFLD #NASH @cddpress https://t.co/Vfeu2FaFb5
Mitochondrial citrate flux and experimental liver disease #NAFLD #NASH @cddpress https://t.co/Vfeu2FaFb5